X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 18.6 35.1 53.0% View Chart
P/BV x 4.4 3.7 117.8% View Chart
Dividend Yield % 0.9 0.3 275.3%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
SUN PHARMA
Mar-18
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs558701 79.7%   
Low Rs362433 83.4%   
Sales per share (Unadj.) Rs116.3110.4 105.3%  
Earnings per share (Unadj.) Rs17.911.0 162.8%  
Cash flow per share (Unadj.) Rs23.117.2 134.3%  
Dividends per share (Unadj.) Rs3.502.00 175.0%  
Dividend yield (eoy) %0.80.4 215.8%  
Book value per share (Unadj.) Rs85.4158.8 53.8%  
Shares outstanding (eoy) m1,023.742,399.26 42.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.05.1 77.0%   
Avg P/E ratio x25.751.6 49.8%  
P/CF ratio (eoy) x19.932.9 60.4%  
Price / Book Value ratio x5.43.6 150.8%  
Dividend payout %19.618.2 107.5%   
Avg Mkt Cap Rs m470,6641,360,021 34.6%   
No. of employees `00011.817.8 66.4%   
Total wages/salary Rs m18,54553,671 34.6%   
Avg. sales/employee Rs Th10,072.714,890.9 67.6%   
Avg. wages/employee Rs Th1,569.13,017.1 52.0%   
Avg. net profit/employee Rs Th1,547.71,480.6 104.5%   
INCOME DATA
Net Sales Rs m119,049264,895 44.9%  
Other income Rs m1,1328,388 13.5%   
Total revenues Rs m120,181273,282 44.0%   
Gross profit Rs m28,47556,081 50.8%  
Depreciation Rs m5,38814,998 35.9%   
Interest Rs m9115,176 17.6%   
Profit before tax Rs m23,30844,295 52.6%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m5,6448,452 66.8%   
Profit after tax Rs m18,29226,338 69.5%  
Gross profit margin %23.921.2 113.0%  
Effective tax rate %24.219.1 126.9%   
Net profit margin %15.49.9 154.5%  
BALANCE SHEET DATA
Current assets Rs m82,005316,359 25.9%   
Current liabilities Rs m60,720198,643 30.6%   
Net working cap to sales %17.944.4 40.2%  
Current ratio x1.41.6 84.8%  
Inventory Days Days7395 77.1%  
Debtors Days Days98108 91.3%  
Net fixed assets Rs m83,703213,178 39.3%   
Share capital Rs m1,0242,399 42.7%   
"Free" reserves Rs m86,421378,606 22.8%   
Net worth Rs m87,445381,006 23.0%   
Long term debt Rs m25,55117,721 144.2%   
Total assets Rs m180,653643,028 28.1%  
Interest coverage x26.69.6 278.1%   
Debt to equity ratio x0.30 628.2%  
Sales to assets ratio x0.70.4 160.0%   
Return on assets %10.64.9 216.9%  
Return on equity %20.96.9 302.6%  
Return on capital %22.010.0 219.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68340,816 104.6%   
Fx outflow Rs m11,24230,143 37.3%   
Net fx Rs m31,44110,673 294.6%   
CASH FLOW
From Operations Rs m9,19339,072 23.5%  
From Investments Rs m-9,737-33,708 28.9%  
From Financial Activity Rs m515-15,393 -3.3%  
Net Cashflow Rs m-29-7,359 0.4%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DR. REDDYS LAB  IPCA LABS  ASTRAZENECA PHARMA  VENUS REMEDIES  PIRAMAL ENTERPRISES  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 383 Points Lower; Realty and Auto Stocks Drag(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Are These Deep Corrections a Buying Signal?(Chart Of The Day)

Oct 5, 2018

The correction has bought many good companies to reasonable valuations. Go against the wisdom of crowd and Buy.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 17, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS